immatics biotechnologies GmbH, a German clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, raised the €12m first tranche of a €34m Series D financing round.
Backers included existing investors dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH.
The company will use the funds to conclude the development of its lead vaccine IMA901, including completing all of the activities necessary to prepare for regulatory filings in the US and Europe.
IMA901 – a cancer vaccine comprising 10 different tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from renal cell carcinoma (RCC) – is in a pivotal phase 3 trial.
It has orphan drug designation in the US and Europe for the treatment of RCC in HLA-A*02 positive patients.
Interim overall survival results are expected in 2014, with final data in 2015.
Led by Paul Higham, CEO, immatics is based in Tuebingen and Martinsried (Munich), Germany and employs 70 people.